Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02665065 | Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia | PHASE3 | ACTIVE NOT_RECRUITING | 153 | — | — | Jun 1, 2016 | Dec 1, 2026 | Jul 18, 2023 | - | — |
| Name | Type | Description |
|---|---|---|
| Iomab-B | DRUG | - |
| Conventional Care | DRUG | - |
| HCT | PROCEDURE | - |